Compare CBAN & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBAN | LUNG |
|---|---|---|
| Founded | 1975 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.6M | 57.9M |
| IPO Year | 1995 | 2020 |
| Metric | CBAN | LUNG |
|---|---|---|
| Price | $20.34 | $1.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 173.4K | ★ 393.9K |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 16.91 | 7.64 |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | $35.41 | $2.48 |
| Revenue Next Year | $4.84 | $18.46 |
| P/E Ratio | $51.46 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $15.00 | $1.13 |
| 52 Week High | $21.61 | $3.88 |
| Indicator | CBAN | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 60.18 | 53.50 |
| Support Level | $19.13 | $1.36 |
| Resistance Level | $21.35 | $1.64 |
| Average True Range (ATR) | 0.36 | 0.12 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 77.78 | 57.78 |
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.